# A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease

> **NCT02271503** · PHASE2 · COMPLETED · sponsor: **Impax Laboratories, LLC** · enrollment: 26 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** CD-LD IR
- **DRUG:** IPX203 180 mg
- **DRUG:** IPX203 270 mg
- **DRUG:** Rytary 195 mg
- **DRUG:** Rytary 145 mg

## Key facts

- **NCT ID:** NCT02271503
- **Lead sponsor:** Impax Laboratories, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2019-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02271503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02271503, "A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02271503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*